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ABSTRACT
Allele-specific expression (ASE) of the Adenomatous Polyposis Coli (APC) gene 
occurs in up to one-third of families with adenomatous polyposis (FAP) that have 
screened mutation-negative by conventional techniques. To advance our understanding 
of the genomic basis of this phenomenon, 54 APC mutation-negative families (21 
with classical FAP and 33 with attenuated FAP, AFAP) were investigated. We focused 
on four families with validated ASE and scrutinized these families by sequencing of 
the blood transcriptomes (RNA-seq) and genomes (WGS). Three families, two with 
classical FAP and one with AFAP, revealed deep intronic mutations associated with 
pseudoexons. In all three families, intronic mutations (c.646-1806T>G in intron 6, 
c.1408+729A>G in intron 11, and c.1408+731C>T in intron 11) created new splice 
donor sites resulting in the insertion of intronic sequences (of 127 bp, 83 bp, and 83 
bp, respectively) in the APC transcript. The respective intronic mutations were absent 
in the remaining polyposis families and the general population. Premature stop of 
translation as the predicted consequence as well as co-segregation with polyposis 
supported the pathogenicity of the pseudoexons. We conclude that next generation 
sequencing on RNA and genomic DNA is an effective strategy to reveal and validate 
pseudoexons that are regularly missed by traditional screening methods and is worth 
considering in apparent mutation-negative polyposis families.
INTRODUCTION
Familial adenomatous polyposis (FAP; OMIM 
#175100) is characterized by a dominant predisposition 
to multiple adenomatous polyps throughout the colon and 
rectum as a consequence of germline mutations in the 
Adenomatous Polyposis Coli (APC) gene [1]. While FAP 
mostly represents an inherited disease, up to 25% may 
result from de novo mutations of APC without any family 
history of the disease [2]. The number of adenomatous 
polyps in the bowel is used to stratify APC-associated 
polyposis into a classical form (FAP; 100 adenomas or 
more) and attenuated form (AFAP; below 100 adenomas). 
These two phenotypes additionally differ relative to the 
onset of polyposis (in the second or third decades of life in 
FAP vs. later in AFAP), colonic location (left-sided disease 
in FAP vs. frequently right-sided disease in AFAP), and 
life-time risk of colorectal cancer (100% in FAP vs. up to 
70% in AFAP) [1, 3].
The APC gene has 16 exons and translation starts 
from exon 2 (http://insight-database.org/genes/APC). 
More than 1,500 unique germline mutations in APC are 
known [4]. The frequency of detectable APC mutations 
in polyposis patients varies a lot depending on the method 
of ascertainment of the patients and families, and the 
strategies used for mutation screening. In a large cohort 
of individuals who had undergone clinical genetic testing 
because of a personal or family history of polyposis, 
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58% (851/1457) of those with classic polyposis and 9% 
(376/4223) of those with AFAP had APC mutations by 
exon-specific sequencing and large rearrangement analysis 
of the APC gene [3]. Moreover, Grover et al. [3] found that 
the APC mutation rate progressively increased with the 
cumulative adenoma count (being 80% in individuals with 
at least one thousand adenomas), while the mutation rate 
of MUTYH, which is another polyposis-associated gene, 
remained constant (below 10 percent) across all polyp 
number categories. Sanger sequencing of genomic DNA 
to examine the coding exons and intron-exon boundaries 
of APC, combined with multiplex ligation-dependent 
probe amplification (MLPA) for large rearrangements is 
the standard mutation screening strategy adopted by most 
laboratories [4]. The protein truncating test (PTT) was 
commonly used in previous years and may be beneficial 
in certain situations [5]. In a typical PTT design, APC 
exons are examined in RNA, except for the last exon 
that is investigated in genomic DNA. Nevertheless, 
over 20% of classical FAP and up to 80% of AFAP 
patients remain APC mutation-negative, which may be 
attributable to methodological shortcomings in association 
with particular types of mutations [5-8], nontruncating 
alterations with uncertain pathogenic significance [2], and 
susceptibility associated with other genes than APC, such 
as MUTYH [3], POLE and POLD [9], and AXIN2 [10].
Unbalanced expression of the two parental alleles, 
due to loss-of-function mutations or various cis- or 
trans-acting factors, may facilitate the identification of 
susceptibility genes for human diseases [11]. APC mutations 
occurring prior to the last exon of the gene are associated 
with allele-specific expression (ASE) [12]. ASE imbalance 
of APC has been found in blood samples from 9 – 31% 
of adenomatous polyposis families without any detectable 
APC mutations by conventional techniques, suggesting the 
existence of hidden mutations [12–14]. Moreover, ASE of 
APC may contribute to common forms of colorectal cancer, 
as colorectal cancer risk has been shown to increase along 
with increasing ASE imbalance [15].
This study was undertaken to address the underlying 
basis of predisposition in 54 APC mutation-negative 
adenomatous polyposis families from Finland, with a 
particular focus on families with constitutionally unbalanced 
mRNA expression of APC alleles by Single Nucleotide 
Primer Extension (SNuPE) [13]. Interrogation of the latter 
four families by whole transcriptome (RNA-seq) and whole-
genome (WGS) sequencing revealed deep intronic mutations 
associated with pseudoexons in three of four families.
RESULTS
Identification of pseudoexons by RNA-seq and 
deep intronic mutations as their underlying 
causes
We focused on three FAP families (42, 85, and 103) 
from the research-based cohort (Figure 1 and Table 1). The 
families were associated with ASE imbalance of APC by 
SNuPE but no identifiable causative change in APC had 
been detected by PTT, Sanger sequencing of all exons 
and intron/exon borders, MLPA, and promoter mutation 
and methylation analyses (ref. [8] and this study). Only 
family 85 included several affected members. Of these, 
85-1 [13] and 85-2 (Supplementary Figure S1) showed 
ASE imbalance, whereas 85-3 was uninformative in ASE 
analysis due to homozygosity for polymorphisms. No 
RNA was available from 85-4.
Blood RNA specimens from the three ASE families 
were subjected to RNA-seq. Data analysis revealed 
aberrant splice junctions which raised a suspicion of 
pseudoexons, i.e., inclusion of intronic sequence in 
the mature mRNA, in families 42 and 85 (Figure 2). 
To verify pseudoexons, APC cDNA was amplified in 
five overlapping fragments with primers described in 
Spier et al. [6] in addition to which primers from exons 
11 (forward) and 13 (reverse) were used to evaluate the 
suspected pseudoexon in family 85 (Supplementary Table 
S1 and Figure 3). Sequencing of reverse transcription 
(RT)-PCR products (fragment 2 in family 42 and fragment 
4 as well as the exon 11-13-specific fragment in family 85) 
revealed a 127-bp insertion from intron 6 in family 42 and 
an 83-bp insertion from intron 11 in family 85.
As the predisposing mutations of the families 
were unknown, WGS on blood DNA was applied. At the 
outset, mutations in the APC coding region and exon/
intron borders had been screened for (see Materials and 
Methods). Particularly, WGS offered the opportunity to 
investigate the entire introns of APC as well as regions 
outside APC. Families 42 and 85 revealed deep intronic 
mutations, both creating new splice donor sites (/gt): 
c.646-1806T>G in intron 6 and c.1408+731C>T in intron 
11 of APC, respectively (Figure 4). The changes were 
validated by Sanger sequencing.
The remaining 51 families (Table 1) were 
subsequently screened by Sanger sequencing with primers 
from introns 6 and 11 of APC (Supplementary Table S1) 
to examine the presence of the deep intronic mutations 
identified in families 42 and 85. These particular mutations 
were absent in the remaining families. Incidentally, 
however, family 163 revealed another nucleotide 
substitution (c.1408+729A>G) two nucleotides upstream 
of the mutation present in family 85 (Figure 4). The 
nucleotide change in family 163 was predicted to activate 
the same cryptic splice donor site (AG/gt) as the mutation 
in family 85 (the nucleotide substitutions created an 
apparently viable AG/ and /gt, respectively) (Figure 5). 
Family 163 represented a clinic-based cohort for which 
only DNA was routinely available. However, we were able 
to obtain RNA from the single affected family member in 
a separate effort. RNA-seq (Figure 2) and RT-PCR (Figure 
3) identified an 83-bp insertion from intron 11, identical 
to that in family 85. Furthermore, the c.1408+729A>G 
mutation was part of the resulting transcript unlike the 
deep intronic mutations of families 42 and 85 (Figure 5). 
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Analysis of the individual RNA reads with pseudoexons 
validated the presence of variant nucleotide (G) at the 
position of the mutation, indicating that the variant 
nucleotide was specifically associated with pseudoexon 
formation (Supplementary Figure S2). Finally, SNuPE 
analysis of cDNA from the index individual from family 
163 showed putative ASE with the value of 1.7 for the 
ratio of allelic peak areas in cDNA relative to genomic 
DNA at rs2229992 (Supplementary Figure S1).
Pathogenicity of pseudoexons
The pseudoexon findings are summarized in Table 
2. The pseudoexons in families 42, 85, and 163 were 
all predicted to cause premature stop of translation; the 
very first three nucleotides of the pseudoexon in family 
42 coded for a stop of translation, whereas in families 
85 and 163 the pseudoexon caused a frameshift and a 
premature stop 55 codons later. The following evidence 
supports the idea that the pseudoexons underlay polyposis 
predisposition in all three families. First, the splice 
prediction program BDGP (Materials and Methods) 
indicated a splice efficiency of 99% for the new splice 
donor sites introduced in intron 6 in family 42 and intron 
11 in family 85. The new splice donor site in intron 11 in 
family 163 did not match with the canonical splice site 
model and was therefore not recognized by the splice 
prediction programs. However, RNA-seq and our cloning 
experiment showed that all pseudoexon-containing 
transcripts had the variant nucleotide G in the 3’ end of 
the pseudoexon (Supplementary Figure S2). Moreover, 
our cloning experiment (on the ex 11 – 13 fragment, see 
legend to Figure 3) combined with haplotype analysis 
(with SNuPE markers) suggested that all transcripts 
representing the mutant allele, as inferred from haplotypes, 
had the pseudoexon inserted (data not shown). Second, the 
intronic variant showed a complete co-segregation with 
polyposis in family 85 (Figure 1). The variants were also 
absent in the general population (ExAC Browser Beta, 
SISu and Ensembl databases and our investigation of 300 
anonymous blood donors from Finland). Finally, WGS 
data available for families 42 and 85 revealed no other 
apparently pathogenic mutations in established cancer 
genes as possible alternative explanations for polyposis 
predisposition.
SNuPE vs. RNA-seq in the detection of ASE
The ASE diagnoses of the four families (42, 85, 103, 
and 163) with unbalanced expression of APC alleles in 
our series (Table 1) were initially based on SNuPE. To 
evaluate if ASE imbalance was also recoverable in RNA-
seq data, a genome-wide ASE imbalance analysis was 
performed as described in Materials and Methods. The 
Figure 1: Pedigrees of ASE families. Pedigrees of adenomatous polyposis families with ASE. Individuals with polyposis and/or 
colorectal cancer are indicated (see Table 1 for additional clinical details). Plus sign denotes carriers of deep intronic mutations associated 
with pseudoexons of APC. Index persons are marked with arrows.
Oncotarget70688www.impactjournals.com/oncotarget
Table 1: Clinical and molecular characteristics of polyposis cases investigated
Case 
IDa
ASE 
statusb
Inheritance 
pattern
Number 
of polyps
Age at 
diagnosisc
Extracolonic
manifestationsd
Classification
of familye
Large 
rearrangement
by MLPAf
APC 
methylation 
by MS-MLPAg
RESEARCH 
BASED
42 ASE Sporadic 100-1000 40 No FAP No No
78 N Sporadic 50 55 No AFAP No No
85-1 ASE dominant 2000 38 Yes FAP No No
85-2 ASE dominant 100-200 16 No FAP No No
85-3 NI dominant 2000 44 No FAP NA No
85-4 dominant 100-200 12 No FAP NA No
88 N sporadic 100-1000 58 No FAP No No
92 N sporadic 200 51 No FAP No No
96 NI sporadic 561 48 No FAP No No
97 N sporadic > 1000 58 No FAP No No
98 dominant 100-1000 30 No FAP No No
100 NI sporadic 30 62 No AFAP No No
103 (ASE) sporadic > 100 51 No FAP No No
104 N dominant? 210 54 Yes FAP No No
111 NI sporadic 30-40 36 No AFAP No No
123 NI sporadic 2100 37 No FAP No No
125 N sporadic 300 31 No FAP No No
CLINIC 
BASED
134 sporadic 200-300 55 No FAP No No
136 sporadic >100 67 Yes FAP No No
139 sporadic 100 71 No FAP No No
145 recessive 20-50 61 No AFAP No No
148 sporadic 150-200 50 No FAP No No
158 sporadic 50 49 Yes AFAP No No
159 sporadic 200 50 No FAP No No
162 sporadic >50 52 No AFAP No No
163 (ASE) sporadic 10-20 16 Yes AFAP No No
165-1 dominant? Colon cancer x 2 50 NA AFAP No No
165-2 dominant? 20-30 33 Yes AFAP No No
168 sporadic 100 56 Yes FAP No No
177 sporadic 100-200 52 No FAP No No
179 dominant? >10 23 No AFAP No No
180 NA >100 38 NA FAP No No
1001 dominant 10 48 NA AFAP No No
1003 sporadic 20-30 70 NA AFAP No No
1005 dominant 10-20 68 Yes AFAP No No
(Continued )
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results are given in Supplementary Table S2. Applying 
stringent criteria for ASE, FAP42 and FAP85 (individual 
85-2) revealed unequivocal ASE for APC (q-value < 
0.05). Three APC-mutation-positive cases not belonging 
to the study series specified in Table 1 were also included, 
and ASE was detected in one (the remaining two were 
uninformative). FAP85 (individual 85-1) and FAP103, 
as well as healthy control sample 3, showed borderline 
ASE which was, however, not statistically significant 
after multiple hypothesis correction (q value > 0.05 and 
≤ 0.15). The ASE value for APC in AFAP163 did not 
reach statistical significance. As shown in Supplementary 
Table S2, the overall concordance between ASE results by 
SNuPE and RNA-seq was high.
DISCUSSION
Canonical splice-site sequences at the intron/exon 
borders define exons. The canonical 5’ (splice donor) site 
has a consensus sequence AG/gtragt and the 3’ (splice 
Case 
IDa
ASE 
statusb
Inheritance 
pattern
Number 
of polyps
Age at 
diagnosisc
Extracolonic
manifestationsd
Classification
of familye
Large 
rearrangement
by MLPAf
APC 
methylation 
by MS-MLPAg
1006 sporadic 20 60 No AFAP No No
1007 sporadic 20 30 No AFAP No No
1010 dominant 5-10 68 NA AFAP No No
1011 NA 60-100 31 NA FAP No No
1013 sporadic >100 48 NA FAP No No
1015 sporadic 10 47 Yes AFAP No No
1017 sporadic? 10-20 57 NA AFAP No No
1018 sporadic 20-30 74 NA AFAP No No
1019 sporadic 2-3 30 Yes AFAP No No
1020 sporadic 3 35 Yes AFAP No No
1021 sporadic 30 72 NA AFAP No No
1022 dominant 3 65 Yes AFAP No No
1023 sporadic 40 33 NA AFAP No No
1024 sporadic 20 72 NA AFAP No No
1025 sporadic 20-30 67 NA AFAP No No
1026 sporadic 10-20 51 NA AFAP No No
1029 sporadic 20-30 56 No AFAP No No
1030 sporadic >10 59 No AFAP No No
1032 NA 8 63 Yes AFAP No No
1034 NA >10 62 No AFAP No No
1035 sporadic 20-30 71 No AFAP No No
1036 dominant >10 61 No AFAP No No
1037 sporadic ~10 52 No AFAP No No
aIdentification number of family, followed by identification number of individual if several family members were studied.
bASE, shows allele-specific expression of APC; (ASE), putative ASE (see Materials and Methods); N, no ASE; NI, not 
informative (homozygous); blank, no RNA available
cPolyposis or colorectal carcinoma, whichever comes first
dDesmoids and duodenal adenomas in particular
eBased on the number of intestinal adenomas with 100 as the cut-off
fP043-C1 assay from MRC-Holland
gME001-C1 assay from MRC-Holland
NA, information not available
Oncotarget70690www.impactjournals.com/oncotarget
acceptor) site poly(y)nyag/G (where capital letters indicate 
exonic and lowercase letters intronic sequence, r denotes 
purine, y pyrimidine, and n any nucleotide, and the nearly 
invariant nucleotides are underlined) [16]. Pseudoexons 
are intronic sequences of 50 – 300 bp in length that have 
apparent 5’ and 3’ splice sites, but are normally ignored 
by the splicing machinery [17, 18]. Pseudoexons can be 
activated by mutations that create viable splice donor 
or acceptor sites by different mechanisms, resulting in 
the insertion of intronic sequences in the mature mRNA 
[19]. Such mutations can be inherited and may cause 
predisposition to cancer syndromes, including ataxia-
telangiectasia (ATM) [20], breast and ovarian cancer 
(BRCA2) [21], Lynch syndrome (MSH2) [22] and familial 
adenomatous polyposis (APC) (ref. [6] and this study). 
From the therapeutic point of view, location far outside the 
coding sequence makes deep intronic mutations excellent 
candidates for correction by antisense oligonucleotides to 
restore the production of normal protein [20, 21].
Using RNA-seq and WGS, we discovered two 
different pseudoexons (127-bp insertion from intron 
6 and 83-bp insertion from intron 11) caused by three 
Figure 2: RNA-seq (42, 85-2, and 163). Sashimi plots to visualize splice junctions. IGV display of RNA-seq data is provided for 
an affected representative of each family and a healthy control individual for reference for each region. Sequence alignments are based 
on TopHat. The region between APC exons 6 and 7 (GRCh37/Hg19) is shown for FAP42 (Figure 2A) and that between exons 11 and 12 
for FAP85 (individual 85-2) and AFAP163 (Figure 2B). The locations of pseudoexons are indicated by horizontal bars. A 54-bp in-frame 
insertion present in the normal reference sample, too, and not associated with any genomic change is denoted by a dashed bar (Figure 
2B). The same insertion was discovered in an earlier investigation [12]. Numbers on the plots indicate APC exon coverages expressed as 
junction depth. Splice events corresponding to pseudoexons are boxed and those associated with the 54-bp insertion are underlined; the 
remaining ones represent canonical splicing.
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different heterozygous germline mutations in APC. To 
our knowledge, our effort is the first one successfully 
identifying pseudoexons in APC using next-generation 
sequencing and the second ever to reveal APC-related 
pseudoexons in FAP. The study by Spier et al. [6] was the 
first report and described two different APC pseudoexons 
(167-bp insertion from intron 5 and 83-bp insertion 
from intron 11). These pseudoexons were caused by 
three different heterozygous germline mutations. By RT-
PCR screen of APC cDNA from 125 APC- and MUTYH 
mutation-negative adenomatous polyposis cases from 
Germany, a frequency of 6.4% (8/125 individuals) was 
obtained for cases with an identifiable genomic change 
underlying pseudoexon formation. Interestingly, the 
pseudoexon in intron 11 occurring in our family 85 in 
association with c.1408+731C>T nucleotide substitution 
was on genomic DNA and RNA level precisely the same 
as that present in two unrelated German patients [6]. The 
region around position +731 in intron 11 may be prone 
to pseudoexon formation in general, given the existence 
of two additional pseudoexon-associated nucleotide 
substitutions in this region, one located two nucleotides 
upstream (our study) and another one six nucleotides 
downstream of position +731 [6]. The overall frequency 
of APC pseudoexons in our series from Finland (3/54 
index patients, 5.5%) may be an underestimate since our 
full pseudoexon screen focused on four index patients 
with unbalanced expression of APC alleles, whereas the 
remaining index patients (with mainly DNA available 
only) underwent a targeted screen for the same mutations 
identified in the former patients.
Diagnostic strategies mostly target coding 
regions in DNA [4]. Detection of disease-associated 
pseudoexons in turn requires simultaneous RNA- and 
DNA-based evidence to demonstrate the insertion 
of extraneous sequence in mRNA and distinguish 
transcriptional post-modification errors from deep 
intronic mutation in genomic DNA as the mechanistic 
basis of insertion. Hence, validated disease-associated 
pseudoexons have remained scarce [6, 20–22], despite 
the fact that potential pseudoexons are frequent in 
introns of human genes [18]. The pseudoexons in 
families 42 and 85 were missed by our original PTT 
screen [23]. Family 42 did reveal a visible truncation, 
Figure 3: RT-PCR (42, 85-1, 163, 103). RT-PCR analysis of samples from ASE families. RT-PCR products separated by gel 
electrophoresis are shown. Arrows denote fragments with intronic insertions (pseudoexons). Fragment 2 (upper panel) encompasses a 
615-bp cDNA segment from exon 4 to exon 9 [6] and shows a heterozygous 127-bp insertion in family 42. The wild-type size of the exon 
11 - exon 13 fragment (lower panel) is 246 bp (Supplementary Table S1). An identical 83-bp insertion in families 85 (case 85-1) and 163 is 
evident. The RT-PCR products from the index persons and healthy controls were cloned and sequenced to verify their DNA sequences. In 
the exon 11 - exon 13 fragment, a 54-bp in-frame insertion (see legend for Figure 2) accompanied the pseudoexon and wild-type sequences 
in a proportion (up to one-third) of all clones and likely contributed to the multiplicity of fragments seen after gel electrophoresis.
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but the subsequent search of a causative change by 
Sanger sequencing of genomic DNA did not extend deep 
into the introns [23]. On the other hand, no convincing 
extra fragment was visible for FAP85. This is likely 
attributable to some commonly observed disadvantages 
of PTT, such as decreased RNA stability and assay 
artifacts [24]. Instead of PTT, family 163 originally 
underwent an exon-by-exon screen in genomic DNA [8] 
that, obviously, was not able to capture deep intronic 
mutations.
Family 103 showed putative ASE imbalance 
(Table 1, Supplementary Table S2), but neither RNA-
seq nor WGS revealed variants that might underlie the 
suggestive ASE phenotype. This apparently sporadic 
case with classical FAP (Figure 1) might be explained 
by a mosaicism for APC mutation; such mutations are 
Figure 4: WGS (42 and 85-2) + Sanger seq. Deep intronic mutations in APC. Upper panels provide IGV display of WGS data for 
intron 6 in FAP42 (Figure 4A) and intron 11 in FAP85, individual 85-2 (Figure 4B). Lower panels show Sanger sequence tracings of the 
mutations. In Figure 4B, the Sanger sequencing result of AFAP163 is also given (AFAP163 was not included in WGS analysis).
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challenging to detect and verify [5]. Eventual in-cis or 
in-trans regulatory changes or complex rearrangements 
escaping detection by sequencing would be examples 
of other theoretical possibilities to consider in future 
investigations. The ASE phenotype in FAP103 affected 
many other genes beyond APC (Supplementary Table S2), 
offering possible candidate genes to be tested for germline 
alterations. It is important to note that up to ~20% of all 
informative genes expressed in lymphoblastoid cells/
blood may show ASE even in healthy control individuals 
Figure 5: Schematic diagrams of pseudoexons. Schematic diagrams of APC pseudoexons identified. The canonical splice sites at 
the exon/intron borders, pseudoexons (underlined), and the responsible deep intronic mutations (in bold) are highlighted.
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[25, 26], and the underlying cause remains elusive for 
most genes.
The site of germline mutation in the APC gene is 
known to correlate with the disease phenotype [1]. Our 
family 42 with pseudoexon 6/7 was associated with 
classical FAP in agreement with genotype-phenotype 
expectations. Among the two pseudoexon 11/12 families, 
family 85 complied with established genotype-phenotype 
correlations by showing classical FAP like the two 
German families with the same mutation. Family 163 was 
classified as AFAP based on polyp count (10 – 20), but also 
showed features more typical (although not exclusive) of 
a profuse form of FAP such as low age at onset (16 years) 
and presence of extracolonic manifestations (mandibular 
osteomas) (Table 1). In FAP85, we demonstrated co-
segregation of the respective genomic change with 
polyposis (Figure 1). Unfortunately, segregation studies 
were not possible in the remaining two families because 
of the lack of additional affected members.
Next-generation sequencing techniques are changing 
the screening for predisposing mutations. Targeted 
gene panels capturing the entire introns in addition to 
exons and combined with deep sequencing are likely to 
replace current screening protocols that rely on exon-
specific Sanger sequencing and MLPA [4, 27]. We show 
that deep intronic mutations of the APC gene explained 
three out of four FAP and AFAP families displaying ASE 
imbalance and remaining mutation-negative by traditional 
methods. This indicates that our strategy to use ASE 
for pre-selection of cases for pseudoexon testing was 
effective and could even serve as a proxy for the initial 
screening of out-of-frame pseudoexon insertion events 
in FAP and AFAP. Unavailability of RNA made ASE and 
pseudoexon screening impossible in a significant fraction 
of our polyposis families (Table 1); hence, investigation 
of larger series is necessary for a reliable determination 
of the frequency and clinical significance of ASE and 
pseudoexon events in this disease. In the clinical context, 
pathogenicity of pseudoexons requires special attention. 
Considerations we point out (see Results above) as well 
as recommendations valid to any splicing aberrations 
[28] would apply. In our experience, next generation 
sequencing on RNA and genomic DNA facilitate 
pseudoexon identification and provide valuable tools to 
explore the genetic basis of mutation-negative families.
MATERIALS AND METHODS
Patients and samples
The series consisted of 54 unrelated families/cases 
from Finland, including 21 with classical FAP and 33 
with AFAP (Table 1). Fourteen families represented a 
research-based cohort from the nation-wide Hereditary 
Colorectal Cancer Registry of Finland [13] lacking APC 
point mutations by PTT and exon-specific screening 
methods (heteroduplex analysis and Sanger sequencing) 
and large rearrangements by MLPA [8] (P043-C1). The 
remaining 40 families represented a clinic-based cohort 
of consecutive index cases with newly diagnosed FAP 
or AFAP and overlapped with the series described in ref. 
[8]. These cases were recruited via clinical genetic units 
of Finnish university hospitals, and cases remaining APC 
mutation-negative after exon-specific sequencing and 
MLPA were eligible (additionally, APC epimutations 
were excluded by methylation-specific multiplex ligation-
dependent probe amplification [8]). MUTYH-positive 
cases and occasional cases with mutations in other 
polyposis-related genes were excluded. Cases with allele-
specific expression (ASE) of APC were 42, 85-1, 85-
2, 103, and 163 (ref. [13] and this study). No ASE was 
detected in cases 78, 88, 92, 97, 104, and 125 [13]. The 
remaining families/cases were uninformative or not tested 
for ASE because of the lack of RNA (as a rule, no RNA 
was available for clinic-based cases).
DNA and RNA were extracted from lymphocytes 
or EBV-transformed lymphoblasts as described [13]. This 
study was approved by the institutional review board 
of the Helsinki University Central Hospital (Helsinki, 
Finland).
Table 2: Summary of the variants
Family Location in APC 
(GRCh37/GRCh38)
Insertion 
length 
(bp)
Genomic 
variant
RNA alteration Predicted 
protein 
alteration
FAP42 intron 6 (5:112126337/5:112790640) 127 c.646-1806T>G r.645_646ins646-1933_646-1807 p.Arg216*
FAP85 intron 11 (5:112158419/5:112822720) 83 c.1408+731C>T
r.1408_1409i
ns1408+647_1408+729 p.Gly471Serfs*55
AFAP163 intron 11 (5:112158417/5:112822722) 83 c.1408+729A>G
r.1408_1409i
ns1408+647_1408+729 p.Gly471Serfs*55
Note: An updated APC nomenclature based on 16 exons (NM_012583R138.4, ENST012583R10257430) was used for exon 
annotation.
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Single nucleotide primer extension (SNuPE)
SNuPE uses a single dideoxynucleotide (ddNTP) 
and a combination of three dNTPs for an extension reaction 
where the incorporation of a ddNTP yields differential 
extension of primers attached close to the polymorphic site 
[13]. Four coding single nucleotide polymorphisms (SNPs) 
in APC were used to study APC allele-specific expression 
(cDNA compared with gDNA) as described in Pavicic et al. 
[8]. ASE ratios (R) were validated against SNuPE results 
from individuals not carrying any APC mutation [8]. Ratios 
R≤0.6 or R≥1.67 were considered to indicate unequivocal 
ASE (40% reduction of one allele relative to the other allele) 
and 0.6<R<0.8 or 1.25<R<1.67 putative ASE (21 – 39% 
reduction of one allele relative to the other allele). The ASE 
statuses in Table 1 were assigned according to the highest 
ASE ratio yielded by any of the four coding polymorphisms.
Transcriptome sequencing (RNA-seq) and 
transcriptome data-analysis
RNA-seq libraries were prepared using the ribo-
depletion protocol from 12 DNAse treated total RNA 
samples, including three from FAP family 85 (individuals 
85-1, 85-2, and 85-3), three from the index persons 
from families 42, 103 and 163, and three from proven 
mutation carriers from APC-mutation positive families 3, 
93, and 63. RNA-seq data for three healthy individuals 
were generated for comparison. Sequencing of samples 
was done using Illumina HiSeq 2000 at the Institute for 
Molecular Medicine Finland (FIMM) (Helsinki, Finland). 
The bioinformatics workflow included correction of the 
sequence data for adapter sequences, bases with low quality, 
and reads less than 36-bp in length using Trimmomatics 
[29]. Paired-end reads passing the pre-processing were 
aligned to human reference genome build 38 (EnsEMBL 
v82) using STAR [30] with the default 2-pass multi-sample 
mapping settings, except that alignSJstitchMismatchNmax 
was set to 0 -1 -1 -1, outSJfilterCountUniqueMin 
to 6 2 2 2, outSJfilterCountTotalMin to 6 2 2 2, and 
outSJfilterDistToOtherSJmin to 10 0 0 0 in order to allow 
a more sensitive recovery of mutations at splice sites. 
Duplicate reads were marked with the Picard tools (http://
picard.sourceforge.net) and strandedness information 
added with Bamutils [31]. Transcripts were assembled 
using StringTie [32] using the EnsEMBL v82 reference 
annotation file. Transcript predictions across all 12 samples 
were combined to a non-redundant set of transcripts using 
default parameters, except that minimum input transcript 
TPM and FPKM were set to 0.5.
RNA-sequencing data variant calling and ASE 
analysis
Allele-specific expression of genes was quantified 
using Genome Analysis Toolkit (GATK) package [33] 
and ASE deceptions algorithm MBASED [34]. Briefly, 
pre-processed and mapped reads were split into exon 
segments using GATK SplitNCigarReads, local indel 
realignment was performed around indels using GATK 
IndelRealigner, and base qualities were recalibrated using 
GATK BaseQualityScoreRecalibration. Variants were 
called using GATK HaplotypeCaller and filtered using 
GATK VariantFiltration according to the best practice 
recommendations regarding the RNA-seq variant analysis 
workflow. Multi allelic sites were removed with GATK 
SelectVariants and non-heterozygous variants and variants 
falling outside of StringTie-called exon regions extended 
by 3 bp discareded with GATK VariantFiltration. The ASE 
deceptions algorithm MBASED [34] was then applied for 
each variant set to infer the probability of ASE in genes 
listed in EnsEMBL v82 and having ≥ 2 variants. Default 
non-phased ASE calling settings were used, except that 
dispersion estimate was set to 0.004 and the probability 
to detected haplotype 1 supporting reads was set to the 
average fraction of aligned reads supporting haplotype 1 
variants with coverage ≥ 30 in the given sample. Sequence 
data was visualized using Integrative Genomics Viewer 
(IGV) browser [35]. Supplementary Table S3 outlines the 
performance of our RNA-seq and ASE experiments.
Whole genome sequencing (WGS)
WGS was applied to DNAs from individuals 85-
1, 85-2, and 85-3 from FAP family 85 as well as index 
patients from FAP families 42 and 103. Briefly, DNA 
was extracted from blood samples and KAPA and 
ThruPLEX sequencing libraries prepared according 
to the manufacturer’s instructions. Sequencing was 
then conducted using Illumina HiSeq 2000 platform 
with KAPA and ThruPLEX libraries at the Institute for 
Molecular Medicine Finland (FIMM) (Helsinki, Finland). 
Sequencing data was analyzed by the FIMM variant 
calling pipeline version (VCP) 3.1 [36], including quality 
control of raw reads before and after alignment, pre-
processing of reads for sequencing artifacts, alignment 
of reads to the human reference genome (build 19) using 
the Burrows-Wheeler Alignment (BWA) software [37], 
and calling of variants with the samtools package [38]. 
The minimum acceptable read depth for a variant was 7. 
Variant data were then analyzed by the VarSeq® software 
version 1.3.2 (Golden Helix, Inc., Bozeman, MT, www.
goldenhelix.com). Genotype quality (difference between 
the Phred-scale likelihoods of the two most likely 
genotypes) was assessed on a scale between 0 and 99 
and variants with genotype quality less than 70 excluded. 
All common variants with minor allele frequency (MAF) 
≥0.001 were removed. Only heterozygote variants were 
considered in agreement with dominant inheritance in 
FAP family 85 and any inheritance pattern was accepted 
in the index patients from FAP families 42 and 103 
(sporadic cases, Table 1). The identified variants were 
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checked against ExAC (http://exac.broadinstitute.org) 
and SISu databases (www.sisuproject.fi) as well as 
Ensembl database (http://www.ensembl.org) to assess 
population frequencies. Sequence data was visualized 
using Integrative Genomics Viewer (IGV) browser [35]. 
Supplementary Table S4 lists some essential performance 
characteristics for the WGS experiments.
Verfication of pseudoexons by sanger sequencing
To verify the pseudoexons identified by RNA-
seq, relevant fragments of APC cDNA were amplified 
with primers from Spier et al. [6] and Sanger sequenced. 
The 11/12 pseudoexon was additionally verified from 
a cDNA fragment from exon 11 to exon 13 (amplified 
with primers given in Supplementary Table S1). 
Moreover, cDNA fragments 2 and exon 11 – 13 (Figure 
3, Supplementary Table S1) were cloned into a pCR2.1 
TOPO vector using the TOPO TA Cloning system 
(Invitrogen, Carlsbad, CA, USA) and DNAs extracted 
from the resulting white colonies were sequenced. The 
genomic variants discovered by WGS were confirmed by 
Sanger sequencing using primers around the respective 
nucleotide substitutions in introns 6 and 11 of APC 
(Supplementary Table S1).
URL addresses for web resources used
Berkeley Drosophila Gene Project (BDGP), http://
www.fruitfly.org/seq_tools/splice.html
Ensembl, http://www.ensembl.org
Exome Aggregation Consortium (ExAC), http://
exac.broadinstitute.org
InSiGHT, http://insight-group.org
Sequencing Initiative Suomi (SISu), www.
sisuproject.fi
PICARD, http://picard.sourceforge.net
GATK, https://software.broadinstitute.org/gatk/
VarSeqTM, http://www.goldenhelix.com
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